ArticleMolecular psychiatry2026
Cognitive trajectories of psychosis risk: temporal patterns and association with progression.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and EEG-ECG mechanisms of taVNS combined with TEAS for negative symptoms of schizophrenia: a protocol for a 2 × 2 factorial randomized controlled trial.European archives of psychiatry and clinical neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive impairment plays a crucial role in the development from clinical high-risk(CHR) to schizophrenia-spectrum psychosis. Understanding its dynamic change trajectories has significant preventive value. This study aims to comprehensively explore the dynamic cognitive trajectories of clinical high-risk(CHR) individuals over a three-year period, compare the trajectories among CHR individuals who convert to psychosis(CHR-C), those who do not(CHR-NC), and healthy controls(HC). This prospective study was part of the Shanghai At Risk for Psychosis(SHARP)-extended program. CHR participants, from psychological counseling outpatient clinics and medication - naive, were followed up at baseline (T1), 2 months ± 1 week (T2), 1 year ± 1 month (T3), 2 years ± 1 month (T4), and 3 years ± 1 month (T5). All participants completed the Chinese version of the MATRICS Consensus Cognitive Battery(MCCB) at these five strictly fixed time points to assess neurocognitive function. Conversion to psychosis was determined as main outcome. A total of 43 CHR(median age, 16[IQR, 15-18] years; 14 men[32.6%]) and 18 HC(median age, 17[IQR, 16-18] years; 8 men[44.4%]) completed five fixed-time cognitive assessments over three years. During the three-year period, CHR individuals were categorized into CHR-C(n = 19) and CHR-NC(n = 24). CHR-C individuals showed more significant cognitive impairments at all time points compared to CHR-NC and HC. The cognitive decline in CHR-C was most prominent in the first year. Growth curve modeling showed that, compared with the HC group, the CHR-C group had a significant negative impact on the composite score of neurocognition(t = -2.809, p = 0.007), and the effect of time is marginally significant(t = -1.911, p = 0.057). The repeated-measures analysis of variance(RMANOVA) indicated significant differences among groups and time-related changes in cognitive scores. Over the entire period, there were highly significant main effects of Time(F = 15.162, p < 0.001, η
Indexed as
Identifiers
41276613What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.